Company: PRME
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001628280-25-008884
Chunk: 190

Company: Prime Medicine, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1A
Chunk 190
---
 our common stock may be influenced by those factors discussed in this “Risk Factors” section and many others, some of which may include: 

•the success of existing or new competitive product candidates or technologies; 

•the timing and results of preclinical studies and clinical trials for any product candidates we may develop; 

•failure or discontinuation of any of our development and research programs; 

•results of any preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; 

•developments or changing views regarding the use of genetic therapies, including those that involve gene editing; 

•commencement or termination of collaborations for our product development and research programs; 

•regulatory or legal developments in the United States and other countries; 

•developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights; 

•the recruitment or departure of key personnel; 

•the level of expenses related to any of our research programs, clinical development programs or product candidates that we may develop; 

•the results of our efforts to develop product candidates; 

•actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts, if any, that cover our stock; 

•announcement or expectation of additional financing efforts; 

•sales of our common stock by us, our insiders or other stockholders; 

•expiration of market stand-off or lock-up agreements; 

•variations in our financial results or those of companies that are perceived to be similar to us; 

•changes in the structure of healthcare payment systems; 

•market conditions in the pharmaceutical and biotechnology sectors; 

•public health crises, pandemics, natural disasters or major catastrophic events; 

•general economic, industry and market conditions; and 

•the other factors described in this “Risk Factors” section.

In recent years, the stock market in general and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. In particular, in relation to uncertainty around inflation and the U.S. Federal Reserve’s measures to slow inflation, the stock market has been exceptionally volatile. Market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company’s securities, securities class action litigation has often been